ImmunityBio (IBRX) Return on Invested Capital (2015 - 2022)

ImmunityBio (IBRX) has 8 years of Return on Invested Capital data on file, last reported at 0.2% in Q2 2022.

• On a quarterly basis, Return on Invested Capital fell 13.0% year-over-year to 0.2% in Q2 2022; TTM through Jun 2022 was 0.2%, a 13.0% decrease from a year earlier, with the FY2020 full-year figure at 0.29%, up 115.0% from the prior year.
• Return on Invested Capital for Q2 2022 stood at 0.2%, down from 0.1% in the prior quarter.
• Over the last five years, Return on Invested Capital for IBRX reached as high as 0.05% in Q3 2021 and fell as low as 0.36% in Q3 2020.
• Historically, Return on Invested Capital has averaged 0.15% across 5 years, with a median of 0.12% in 2019.
• Across the five-year window, Return on Invested Capital dropped 24 bps in 2020 and surged 31 bps in 2021, its largest moves.
• Year by year, Return on Invested Capital stood at 0.09% in 2018, then slumped by 68 bps to 0.15% in 2019, then gained by 1 bps to 0.15% in 2020, then soared by 57 bps to 0.07% in 2021, then tumbled by 200 bps to 0.2% in 2022.
• Per Business Quant data, the three most recent Return on Invested Capital figures were 0.2% in Q2 2022, 0.1% in Q1 2022, and 0.07% in Q4 2021.